It absolutely was one of these astounding “we’re living in the future” moments.
The partnership between IBM and the world ’s top cancer research institutions is coming apart. The project is on hold and has been since last year. MD Anderson is requesting bids from other contractors who might replace IBM in future efforts. The report, however, states: “Results stated herein shouldn’t be interpreted as functional capabilities of the system in its present state or an opinion on the scientific basis.”
“When it was proper to do this, the job was put on hold. As a public organization, we decided to go out to the marketplace for competing bids to find where the industry has advanced.”
The disclosure comes at an uncomfortable minute for IBM. Investments like these may pay dividends, but early technology adoption doesn’t always result in a win. The ending of the MD Anderson collaboration looks bad. Even in the event the choice is as much a result of red tape or MD Anderson’s mismanagement — which it might be — it continues to be a setback for a field without any huge successes.
But IBM defended the MD Anderson data, known as OEA or the Oncology Expert Advisor. It says the OEA’s recommendations were precise, agreeing with experts 90% of the time. “ Anderson chose to take it forwards,”, The OEA R&D project was a success, and likely could have been deployed had MD says an IBM spokesperson.
In March 2012, IBM signed a deal with Memorial Sloan-Kettering Cancer Center in New York to create a commercial product that will use the same technology to examine the medical literature and help doctors pick treatments for cancer patients.
Based on the audit report, Chin went around regular processes to cover the pricey undertaking, even making sure payments to IBM were low enough that will have required her to get acceptance from MD Anderson’s board. She additionally didn’t get approval from the information technology department.
He also notes that payments seem to have been made from donations that hadn’t been received.
Despite all this play, initial reports on the MD-Anderson/Watson cooperation were favorable. ’s recommendations The Washington Post said MD Anderson physicians-in-training were amazed by the machine in 2015. “I was surprised,” one told the newspaper. “Even in the event you work all night, it will be impossible to have the ability to put this much data together like that.”
In September, IBM ceased supporting the product, last November, according to the audit, which was made. Last week, The Houston Chronicle along with the Cancer Letter reported on the audit. Forbes got a copy of a request for proposals verifying that MD Anderson is buying a firm to take on IBM’s job. In a statement, MD Anderson stated that it wasn’t excluding companies that had formerly worked from occupation with it, implying that it may choose to really go with IBM to reboot the endeavor.
Meanwhile, IBM now sells. The aim, just like the MD Anderson product, is to assist physicians with picking treatments. With no computer, this is done with a so-called “tumor board,” a group of pros who meet weekly. IBM points to a more than ten studies presented at academic meetings showing that Watson’s recommendations agree with those of tumor boards.
When IBM CEO Rometty makes her statements at HIMSS, the well-being-technology conference, the question for investors and doctors will be this: are they more like the Memorial Sloan Kettering attempt, which seems to have resulted in a real product? Or are they like the mess that generally seems to have occurred at MD Anderson?
Excerpted from an article originally posted at Forbes.